ES2062235T3 - Variantes de aprotinina y procedimiento gentecnico para la fabricacion microbiana de estas variantes en forma procesada homogenea. - Google Patents

Variantes de aprotinina y procedimiento gentecnico para la fabricacion microbiana de estas variantes en forma procesada homogenea.

Info

Publication number
ES2062235T3
ES2062235T3 ES90116631T ES90116631T ES2062235T3 ES 2062235 T3 ES2062235 T3 ES 2062235T3 ES 90116631 T ES90116631 T ES 90116631T ES 90116631 T ES90116631 T ES 90116631T ES 2062235 T3 ES2062235 T3 ES 2062235T3
Authority
ES
Spain
Prior art keywords
variants
gentechnical
homogenous
procedure
processed form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90116631T
Other languages
English (en)
Inventor
Jurgen Dr Ebbers
Dietrich Dr Horlein
Michael Dr Schedel
Rathindra Dr Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2062235T3 publication Critical patent/ES2062235T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL INVENTO CONCIERNE A LOS VARIANTES RECOMBINANTES DE APROTININA, AL PEOCEDIMIENTO DE PRODUCCION DE DICHOS VARIANTES PEPTIDICOS COMO PRODUCTOS DE SECRECION PROCESADOS HOMOGENEAMENTE POR LEVADURAS TRANSFORMADAS, ASI COMO A LOS MEDICAMENTOS QUE CONTIENEN ESTOS VARIANTES RECOMBINANTES DE APROTININA.
ES90116631T 1989-09-13 1990-08-30 Variantes de aprotinina y procedimiento gentecnico para la fabricacion microbiana de estas variantes en forma procesada homogenea. Expired - Lifetime ES2062235T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3930522A DE3930522A1 (de) 1989-09-13 1989-09-13 Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben

Publications (1)

Publication Number Publication Date
ES2062235T3 true ES2062235T3 (es) 1994-12-16

Family

ID=6389306

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90116631T Expired - Lifetime ES2062235T3 (es) 1989-09-13 1990-08-30 Variantes de aprotinina y procedimiento gentecnico para la fabricacion microbiana de estas variantes en forma procesada homogenea.

Country Status (15)

Country Link
US (1) US5164482A (es)
EP (1) EP0419878B1 (es)
JP (1) JP2916228B2 (es)
KR (1) KR0169976B1 (es)
AT (1) ATE113074T1 (es)
AU (1) AU632361B2 (es)
CA (1) CA2025070C (es)
DD (1) DD299311A5 (es)
DE (2) DE3930522A1 (es)
DK (1) DK0419878T3 (es)
ES (1) ES2062235T3 (es)
FI (1) FI104724B (es)
HU (1) HU213582B (es)
IL (1) IL95618A (es)
ZA (1) ZA907266B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
US5056341A (en) * 1989-06-08 1991-10-15 Sanyo Electric Co., Ltd. Washing machine
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
IL99585A0 (en) * 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
DE19629982A1 (de) * 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
EP1406652A2 (en) * 2001-07-10 2004-04-14 Omnio AB Novel drug targets for arthritis
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
EP1929017B1 (en) 2005-09-16 2011-12-07 Bayer CropScience AG Transplastomic plants expressing lumen-targeted protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037806A (en) * 1985-02-22 1991-08-06 Monsanto Company Biologically active method using somatotropins
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid

Also Published As

Publication number Publication date
CA2025070C (en) 2001-01-02
EP0419878A1 (de) 1991-04-03
KR910006483A (ko) 1991-04-29
EP0419878B1 (de) 1994-10-19
JPH03197496A (ja) 1991-08-28
FI104724B (fi) 2000-03-31
HU213582B (en) 1997-08-28
US5164482A (en) 1992-11-17
HU905877D0 (en) 1991-03-28
ATE113074T1 (de) 1994-11-15
FI904474A0 (fi) 1990-09-11
AU6245390A (en) 1991-03-21
IL95618A0 (en) 1991-06-30
DE3930522A1 (de) 1991-03-21
IL95618A (en) 1996-09-12
AU632361B2 (en) 1992-12-24
CA2025070A1 (en) 1991-03-14
HUT62031A (en) 1993-03-29
JP2916228B2 (ja) 1999-07-05
ZA907266B (en) 1991-07-31
DD299311A5 (de) 1992-04-09
DE59007498D1 (de) 1994-11-24
DK0419878T3 (da) 1994-11-21
KR0169976B1 (ko) 1999-02-01

Similar Documents

Publication Publication Date Title
ES2062235T3 (es) Variantes de aprotinina y procedimiento gentecnico para la fabricacion microbiana de estas variantes en forma procesada homogenea.
EP2145897A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
NZ228130A (en) Therapeutic composition comprising fenofibrate and a solid surfactant which has been co-micronised; preparatory process
GR3019901T3 (en) Osteoinductive pharmaceutical formulations
DE59000270D1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
GB2181138B (en) Recombinant alveolar surfactant protein
ATE156361T1 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
CA2031430A1 (en) Process for refolding recombinantly produced tgf-.beta.-like proteins
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
CA2093659A1 (en) Dna sequence encoding bovine .alpha.-lactalbumin and methods of use
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
ES2103538T3 (es) Formulacion de levadura para la preparacion de productos horneados.
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
CA2247998A1 (en) Fragments of cr1 and their use
AU639827B2 (en) New peptide and pseudopeptide compounds that are therapeutically active in the blood coagulation cascade, process for the preparation thereof, and pharmaceutical compositions containing them
AU3117093A (en) New peptide and pseudopeptide compounds which are therapeutically active in the blood coagulation cascade, process for preparing them and pharmaceutical compositions containing them
IT1264562B1 (it) Composizione farmaceutica per l'applicazione topica di 17,b estradiolo nel trattamento della cheratocongiuntivite sicca
MD421C2 (ro) Derivaţi ai aminoacizilor şi sărurile acido-aditive ale acestora

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 419878

Country of ref document: ES